A new jigsaw piece to potentially improve personalised treatment for Crohn’s Disease

8th October 2019

Earlier this year a UK wide collaboration led by the University of Exeter and the Royal Devon & Exeter NHS Foundation, and funded by Guts UK, revealed that early personalised treatment could help people with Crohn’s disease to get a more effective therapy1.

The immune system (our natural defensive mechanism) does not function properly in people with Crohn’s disease. They produce a molecule, called TNF (anti-tumour necrosis factor) that drives persistent gut inflammation. The use of drugs that interfere with TNF (anti-TNF drugs called Infliximab and Adalimumab) has greatly advanced the treatment of Crohn’s disease. They are commonly used to treat people when other medicines are not working. However only half of patients show any benefit, and for some the effect of the drugs decrease over time.

Until now, there has been no way of predicting how people with Crohn’s disease would respond to these treatments. One reason patients lose response is because their body recognises the drug as a threat, and they produce antibodies (soldiers of our immune system) to attach to it. As a result, the treatment can’t work properly.

“Without the initial funding from Guts UK, this study probably wouldn’t have happened. Thank you to Guts UK for your support”

– Claire Bewshea, a member of the research team.

In an important study funded by Guts UK and published in the journal Gastroenterology2 this week, Dr Ahmad and colleagues from Exeter have confirmed that these antibodies against anti-TNF drugs are an important cause of treatment failure. For the first time, they have also shown that these antibodies are more common amongst patients with a variation in a specific region of the DNA (the cell’s instruction manual), called HLA-DQA1*05. This variation is present in 40 percent of the European population and people carrying it are twice likely to produce these antibodies. Ultimately, this suggests that for those carrying HLA-DQA1*05, anti-TNF drugs may not be the first-choice drug. These findings will help identifying the right drug for the right patient first time.

Dr Manuela Volta, Research Manager at Guts UK

“At Guts UK we are delighted to have supported this ground-breaking study. This is an important step towards the goal of personalised medicine for those with Crohn’s disease or colitis (which is around 1 in 200 people). 

We will need a further trial to confirm genetic testing before we can begin treating those with Crohn’s and colitis with more effective and personalised treatments” 

Research like Dr Ahmad's is funded by Guts UK thanks to the generosity of our supporters. Guts UK is committed to fighting all digestive diseases, and we could not do it without your support. Click here to support our important work.

Learn more:

Read more posts...

Your Comments: Mental Health Awareness Week

Digestive symptoms and conditions can have a real impact upon every-day life, that our community sometimes find others can underestimate. Managing pain, being unable to predict symptoms from day-to-day and anxiety surrounding accessing near-by toilet...

22nd May 2020

Mental Health Awareness & Digestive Diseases

Mental Health Awareness Week 2020 falls at a challenging time for many across the globe. The team at Guts UK recognise the impact that digestive diseases can have on your mental health, and this week...

20th May 2020

World IBD Day

On World IBD Day every year, patient organisations come together from all over the globe to raise awareness of Crohn’s disease & Colitis. Guts UK is proud to fund over 10 current active research projects into...

19th May 2020

Eosinophilic Awareness Week 2020

This week, Guts UK wants to raise awareness, encourage collaboration and research into eosinophilic diseases. What are Eosinophilic Diseases? Eosinophilic Diseases (pronounced ee-oh-sin-oh-fil-ik) that affect the gut are identified by the presence of a type...

18th May 2020

World Barrett’s Day

Guts UK is one of the many worldwide charities collaborating to raise awareness of Barrett’s oesophagus for the first ever World Barrett’s Day – 16th May 2020. What is Barrett’s oesophagus? Around 10% of persistent...

16th May 2020

Coeliac Awareness Week – Lockdown as a Coeliac Dietitian

Cristian Costas, coeliac dietitian shares his experience supporting patients with coeliac disease during these challenging times. What was your role before lockdown and COVID-19? I was running the dietetic-led coeliac service at Bradford Teaching Hospitals...

12th May 2020

Cancer Treatment & Covid-19

On Monday, the Health Secretary announced that hospitals are now restarting vital services including cancer care. An important part of our work at Guts UK is campaigning, raising awareness and calling for more research into...

29th April 2020

Creon 25k – Potential Short Term Stock Issues

Guts UK is the only UK charity funding a research fellowship into pancreatitis. Pancreatitis is a priority for our charity, so each November we’re proud to run a month-long Kranky Panky Pancreatitis Awareness Campaign. We...

22nd April 2020

Vitamin D Supplements & Covid19

Vitamin D levels tend to be low in people living in Northern Europe during winter months. Vitamin D is synthesised in the skin by the action of ultraviolet in sunlight. Although it is also present...

26th March 2020

World Digestive Health Day 2020

Happy World Digestive Health Day! Today is a much awaited day on the Guts UK calendar. Guts UK is the only UK charity funding research into the digestive system from top to tail; the gut,...

29th May 2020